Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Simcere Pharmaceutical Group Limited has announced the signing of an exclusive agreement with TargetRx to commercialize a new non-small cell lung cancer drug, TGRX-326, in mainland China. The deal includes an initial payment of over $20 million to TargetRx, which will also receive compensation for promotional services. TGRX-326, a promising treatment for ALK/ROS1 positive fusion gene-driven cancer, has shown notable efficacy and safety in early trials and has the potential to treat brain metastases due to its high blood-brain barrier permeability.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.